Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR ‐1236‐3p/ FGF7 axis in breast cancer
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Bo Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, People's Hospital of Shenzhen Baoan District, Shenzhen, China. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Circular RNAs (circRNAs) are closely associated with the development of breast cancer (BC). In this study, we aimed to clarify how differentially expressed circRNAs affect the development of BC.
Methods
Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to detect the expression of circADAM9, miR‐1236‐3p and fibroblast growth factor 7 (FGF7). Colony formation, 5‐ethynyl‐2′‐deoxyuridine (EdU), wound healing, transwell, and flow cytometry were used to assess cell proliferation, migration, invasion, and apoptosis. Glucose consumption, lactic acid production and ATP levels were assessed using glycolysis metabolism analysis. Dual‐luciferase reporter assay and RNA immunoprecipitation (RIP) assay were carried out to verify the relationship between miR‐1236‐3p and circADAM9 or FGF7. The roles of cirADAM9 on tumor growth were analyzed using a xenograft tumor model. Ki‐67 and FGF7 expression was measured via immunohistochemistry (IHC) assay. Apoptosis‐related proteins and exosome markers were detected by western blot.
Results
CircADAM9 was highly expressed in BC cells, and circADAM9 silencing inhibited BC cell proliferation, migration, invasion, and glycolysis, and promoted cell apoptosis. Furthermore, miR‐1236‐3p inhibition could overturn circADAM9 knockdown‐mediated BC inhibition. Moreover, the negative influences of miR‐1236‐3p overexpression on BC progression were restrained via FGF7 overexpression. CircADAM9 silence also inhibited BC tumor growth in vivo.
Conclusion
CircADAM9 promoted BC development partly by the miR‐1236‐3p/FGF7 axis, highlighting a potential prognostic biomarker and therapeutic target for BC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, People's Hospital of Shenzhen Baoan District, Shenzhen, China.
- Department of Thyroid and Breast Surgery, People's Hospital of Shenzhen Baoan District, Shenzhen, China.
ORCID-Profile: Jianshan Lin
Zitieren
APA
Huang, B., Zhang, Y., Sun, P., Lin, J., & Wang, C. (2023). Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR ‐1236‐3p/ FGF7 axis in breast cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15025
Vancouver
Huang B, Zhang Y, Sun P, Lin J, Wang C. Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR ‐1236‐3p/ FGF7 axis in breast cancer. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15025
BibTeX
@article{Huang2023,
author = {Huang, Bo and Zhang, Yichao and Sun, Peng and Lin, Jianshan and Wang, Cunchuan},
title = {Knockdown of circADAM9 inhibits cell progression and glycolysis by targeting the miR ‐1236‐3p/ FGF7 axis in breast cancer},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15025}
}
EUVIMED